Skip to content
PeptideNot WADA ProhibitedCompare

Oxytocin

Also known as: Pitocin, Syntocinon, Induxin, OT, 'Love hormone', 'Bonding hormone'

1
1 · Natty510 · Enhanced

Lower numbers = closer to natural. Higher numbers = more enhanced.

Why this rating?

Oxytocin is an endogenous nonapeptide hormone (nine amino acids) made in the hypothalamus and released by the posterior pituitary. Its FDA-approved medical role is obstetric (inducing/augmenting labor and controlling postpartum hemorrhage), and its non-medical interest is social/emotional, bonding, trust and anxiety modulation, mostly studied via intranasal dosing. It is not anabolic, does not build muscle or burn fat, does not raise testosterone/GH or any anabolic hormone, and does not enhance athletic performance in any way, so it does not move the natural muscular/physique/performance ceiling at all. Rated 1: basically natty, no effect on the muscular/physique scale.

Overview

A nine-amino-acid peptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, a disulfide-bridged nonapeptide) produced in the hypothalamus and released by the posterior pituitary. Medically it is an FDA-approved injectable used to induce/augment labor and control postpartum bleeding. Popularly nicknamed the 'love' or 'bonding' hormone, it is studied intranasally for its effects on social behavior, trust, and anxiety. None of which are performance-enhancing in the athletic sense.

Purpose & Use Cases

Obstetric (FDA-approved)

Injectable oxytocin is FDA-approved to induce or augment labor and to control postpartum hemorrhage / aid placental delivery. This is a hospital, clinician-titrated use, not a self-administered one.

Milk Let-Down

By contracting mammary myoepithelial cells it drives the milk-ejection reflex; an intranasal formulation was historically used to encourage postpartum milk let-down.

Social / Bonding (research)

Intranasal oxytocin is studied for effects on trust, generosity, social bonding, and reducing fear/anxiety. Evidence is mixed and effects are subtle, not a reliable enhancement.

Benefits

  • Endogenous hormone with a well-defined, FDA-approved obstetric role
  • Drives the milk let-down reflex
  • Studied for social bonding, trust, and reduced anxiety (intranasal)
  • Not hormonally suppressive of the HPTA / testosterone
  • Short-acting and, at research intranasal doses, generally well tolerated

Good to Know

A real hormone, not a muscle drug

Oxytocin is a genuine posterior-pituitary hormone with an FDA-approved obstetric use (labor and postpartum bleeding). Its non-medical appeal is emotional/social (bonding, trust, calm) not muscle, strength, or fat loss. It does not touch the HPTA.

Intranasal is the research route, and effects are subtle

The "love hormone" reputation comes from intranasal studies showing effects on trust, generosity and fear, most use a single acute dose, with the majority of trials standardizing on 24 IU (documented range across studies: 1-48 IU; Barton et al. 2025). Findings are mixed even at that standard dose, there is no established, reliable enhancement protocol, and intranasal delivery to the brain is itself debated.

The dangerous side is in the drip, not the spray

The scary adverse effects (water intoxication/low sodium, uterine hyperstimulation, arrhythmia) come from high-dose IV infusion during labor. Single low-dose intranasal research use is generally well tolerated, but that is not the same as being validated or risk-free.

Dosage Guidelines

Experience LevelDosage Range
Beginner8 – 16 IU/day
Intermediate20 – 24 IU/day
Advanced32 – 48 IU/day
Frequency
Almost all social-cognition/bonding research uses a single acute intranasal dose per test session, not a repeated daily self-administration protocol. A minority of longer clinical trials (e.g. autism, schizophrenia) use daily or twice-daily intranasal dosing over several weeks. Obstetric use is a separate, clinician-titrated IV/IM infusion protocol and is not represented by the figures above.
Typical Cycle Length
1 – 4 weeks
Notes

The 8-48 IU intranasal range reflects doses documented in human social-neuroscience research, not a self-administration or bodybuilding protocol. A 2025 systematic review (Barton et al., Neurosci Biobehav Rev) found studies used doses from 1 IU to 48 IU, with the majority standardizing on 24 IU; the original "trust study" paradigm (Kosfeld et al., Nature 2005) also used 24 IU. No standardized human-enhancement dose exists. Treat any intranasal "protocol" as experimental. Obstetric dosing is unrelated and clinician-titrated (labor induction ~0.5-2 mIU/min IV, increased 1-2 mIU every 15-40 min; postpartum hemorrhage: 10 units IM or 60-200 mIU/min IV, StatPearls). Intranasal half-life is ~2 hours vs 1-6 minutes IV.

Side Effects

Water Intoxication / Hyponatremia

uncommon
Severity
4/5

Oxytocin has an antidiuretic effect; with high doses and large fluid volumes it can cause water retention, low sodium, and in severe cases seizures, a recognized risk of the medical (infusion) setting.

Mitigation

A clinical concern managed by controlling fluids and dose during medical use; not typically relevant to single intranasal doses.

Uterine Hyperstimulation

uncommon
Severity
4/5

Excessive or too-frequent uterine contractions during labor induction, which can distress the fetus. Specific to the obstetric use.

Mitigation

Managed by clinicians via infusion titration and monitoring.

Cardiovascular Effects

uncommon
Severity
3/5

Cardiac arrhythmias and blood-pressure changes (including severe hypertension) have been reported, mainly in the medical infusion context.

Mitigation

Medical monitoring; not a common issue with low-dose intranasal research use.

Injection / Nasal Irritation

uncommon
Severity
1/5

Local irritation at the administration site.

Mitigation

Generally mild and transient.

General Mitigation Strategies

The serious adverse effects (hyponatremia/water intoxication, uterine hyperstimulation, arrhythmia, severe hypertension) are essentially confined to the medical infusion setting and are managed by clinicians. Intranasal research doses are generally well tolerated. Because sourcing of non-pharmaceutical intranasal oxytocin is unregulated, purity and dose accuracy vary. Verify any product.

Post Cycle Therapy (PCT)

✓PCT Not Required

Not an anabolic/androgenic agent. Does not suppress the HPTA. No PCT required.

How It Works

Oxytocin acts on the oxytocin receptor, a G-protein-coupled receptor. In the uterus it triggers a rise in intracellular calcium in the myofibrils, driving smooth-muscle contraction; in the breast it contracts the myoepithelial cells around the mammary alveolar ducts, producing the milk let-down (ejection) reflex. Centrally it modulates social bonding, trust, and fear/anxiety circuits, which is the basis for the intranasal research use. It has no anabolic, androgenic, or metabolic muscle-building action.

Fundamentals

Reference on the practices relevant to Oxytocin: how they are done and where they go wrong. Not a recommendation to use it.

Reconstitution & concentration math→

Turning this powder into a measured dose

Bloodwork: what to measure and when→

The markers that matter here

Warning signs & when to seek care→

When to stop and get help

WADA Status

✓Not Prohibited by WADA

Oxytocin is not named on the WADA Prohibited List. S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) covers substances such as erythropoietins, growth hormone, gonadotropins (hCG/LH), corticotrophins, IGF-1 and specific growth factors. Oxytocin is not among them, and it has no established muscle-building or performance-enhancing effect. (The current WADA list could not be opened directly this session to double-check; status is stated as not-prohibited based on it not appearing on any published list or named S2 substance category.)

References

Last updated: July 19, 2026